NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more
Market Cap & Net Worth: NGL Fine-Chem Limited (NGLFINE)
NGL Fine-Chem Limited (NSE:NGLFINE) has a market capitalization of $155.51 Million (₹13.47 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #22276 globally and #1153 in its home market, demonstrating a -9.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NGL Fine-Chem Limited's stock price ₹2179.90 by its total outstanding shares 6178024 (6.18 Million).
NGL Fine-Chem Limited Market Cap History: 2022 to 2026
NGL Fine-Chem Limited's market capitalization history from 2022 to 2026. Data shows growth from $109.40 Million to $155.51 Million (4.30% CAGR).
NGL Fine-Chem Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NGL Fine-Chem Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
NGL Fine-Chem Limited's market cap is 0.03 times its annual revenue
0.94x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.47x
NGL Fine-Chem Limited's market cap is 0.47 times its annual earnings
15.99x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $109.40 Million | $3.18 Billion | $498.97 Million | 0.03x | 0.22x |
| 2023 | $159.00 Million | $2.78 Billion | $204.96 Million | 0.06x | 0.78x |
| 2024 | $129.20 Million | $3.39 Billion | $413.17 Million | 0.04x | 0.31x |
| 2025 | $100.31 Million | $3.68 Billion | $211.24 Million | 0.03x | 0.47x |
Competitor Companies of NGLFINE by Market Capitalization
Companies near NGL Fine-Chem Limited in the global market cap rankings as of March 18, 2026.
Key companies related to NGL Fine-Chem Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
NGL Fine-Chem Limited Historical Marketcap From 2022 to 2026
Between 2022 and today, NGL Fine-Chem Limited's market cap moved from $109.40 Million to $ 155.51 Million, with a yearly change of 4.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹155.51 Million | +55.02% |
| 2025 | ₹100.31 Million | -22.36% |
| 2024 | ₹129.20 Million | -18.74% |
| 2023 | ₹159.00 Million | +45.33% |
| 2022 | ₹109.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of NGL Fine-Chem Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $155.51 Million USD |
| MoneyControl | $155.51 Million USD |
| MarketWatch | $155.51 Million USD |
| marketcap.company | $155.51 Million USD |
| Reuters | $155.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.